Global Perspectives in Early-Stage Lung Cancer in 2023
Early lung cancer-specific discussions on therapeutic advances and their application in clinical decision-making
December 15, 2023
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
Faculty Members
Nasser Hanna, MD
Indiana University Health, Indianapolis, IN, USA
Andrew Haas, MD, PhD
Penn Medicine, Philadelphia, PA, USA
Jonathan Spicer, MD, PhD
McGill University, Montreal, QC, Canada
Lynette Sholl, MD
Brigham and Women’s Hospital, Boston, MA, USA
Charles Simone II, MD, FASTRO, FACRO
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland
Enriqueta Felip, MD, PhD
Vall d’Hebron University, Barcelona, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative?
- Oncogene-Driven NSCLC: EGFR/ALK – Do These Approaches Complement or Replace Chemotherapy?
- The Road Forward for Other Drivers and Targets in Resectable NSCLC
- Predictive Markers: Who Needs More Therapy, Who Needs Less?
